An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...